MIM
THRX

MetLife Investment Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

MetLife Investment Management’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,330
Closed -$96.4K – 3001
2023
Q2 		$96.4K Hold
10,330
– – ﹤0.01% 2702
2023
Q1 		$91.7K Buy
+10,330
New +$101K ﹤0.01% 2589

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

MetLife Investment Management's THRX Position: Q3 2023 in Review

MetLife Investment Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q3 2023, closing a stake of 10,330 shares — an estimated $96.4K sold.

MetLife Investment Management first reported a position in THRX in Q1 2023 and held it in 2 quarters. The position peaked at $96.4K in Q2 2023. 63 funds tracked by Wall St. Rank hold THRX as of Q3 2023.

  • MetLife Investment Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 10,330 Theseus Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $96.4K.
  • MetLife Investment Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • MetLife Investment Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $96.4K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.